News

Filter

Current filters:

secukinumab

1 to 9 of 13 results

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

17-10-2014

The US Food and Drug Administration's advisory panel has voted to keep a black box warning on US pharma…

ChantixNovartisPfizerPharmaceuticalRegulationsecukinumabUSA

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

Novartis' secukinumab shows strong efficacy in psoriasis Phase III trials

10-10-2014

Swiss drug major Novartis has reported data from a Phase III trial showing consistent efficacy in clearing…

DermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

1 to 9 of 13 results

Back to top